New combo therapy targets rare bile duct cancer gene
NCT ID NCT06728410
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs (pemigatinib and durvalumab) can shrink or control advanced bile duct cancer that has a specific FGFR2 gene change. About 38 adults whose cancer has not responded to prior treatment will receive daily pills and an IV infusion every 3 weeks. The goal is to see how many patients have their tumors shrink or stop growing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FGFR2 GENE MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
- Can matching drugs to tumor genes beat biliary cancer?
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?
- Triple attack on bile duct cancer: chemo, targeted drug, and immunotherapy aim to make the inoperable operable